Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2012
|
| gptkbp:ATCCode |
L04AA31
|
| gptkbp:blackBoxWarning |
hepatotoxicity
teratogenicity |
| gptkbp:CASNumber |
163451-81-8
|
| gptkbp:chemicalFormula |
C12H9F3N4O2
|
| gptkbp:contraindication |
pregnancy
severe hepatic impairment |
| gptkbp:drugClass |
immunotherapy
|
| gptkbp:eliminationHalfLife |
18–19 days
|
| gptkbp:genericName |
gptkb:teriflunomide
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aubagio
|
| gptkbp:indication |
relapsing forms of multiple sclerosis
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Sanofi
|
| gptkbp:mechanismOfAction |
dihydroorotate dehydrogenase inhibitor
|
| gptkbp:pregnancyCategory |
gptkb:X_(US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea hypertension increased liver enzymes hair thinning |
| gptkbp:synonym |
gptkb:teriflunomide
|
| gptkbp:usedFor |
multiple sclerosis
|
| gptkbp:bfsParent |
gptkb:Sanofi
|
| gptkbp:bfsLayer |
5
|